Vertex Sees Lowered Estimates and 3 Must-See Stock Analyses

Rudolph Technologies Inc. (NASDAQ:RTEC): After Rudolph Technologies Inc. agreed to buy Azores Corp., Stifel believes that the arrangement increases Rudolph’s presence in the key back-end packaging lithography segment. The firm thinks that the deal could drive market share gains for Rudolph over time and they maintain a Buy rating on the stock.

Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP): After Endo Pharmaceuticals Holdings Inc.’s Chief Executive Officer announced that he would retire next year, Stifel anticipates  the company’s board “to explore all strategic options,” including M&A. The firm maintains a $40 price target and Buy rating on the shares.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): Goldman reduced Vertex Pharmaceuticals Incorporated’s earnings estimates to reflect lower Incivek sales ahead of competitor launches. The firm gives their shares a Sell rating.

Charles River Laboratories International, Inc. (NYSE:CRL): Following conservative but disappointing 2013 guidance, Baird lowered their price target on Charles River Laboratories International, Inc. The firm conceded that they are not a top pick, but believes their underlying fundamental strength and attractive valuation warrant their Outperform rating.

Investing Insights: Will Vivus’s Stock Price Continue to Shed Weight?